These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 28487502)

  • 1. PDCD1 (PD-1) promoter methylation predicts outcome in head and neck squamous cell carcinoma patients.
    Goltz D; Gevensleben H; Dietrich J; Schroeck F; de Vos L; Droege F; Kristiansen G; Schroeck A; Landsberg J; Bootz F; Dietrich D
    Oncotarget; 2017 Jun; 8(25):41011-41020. PubMed ID: 28487502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene promoter methylation signature predicts survival of head and neck squamous cell carcinoma patients.
    Kostareli E; Hielscher T; Zucknick M; Baboci L; Wichmann G; Holzinger D; Mücke O; Pawlita M; Del Mistro A; Boscolo-Rizzo P; Da Mosto MC; Tirelli G; Plinkert P; Dietz A; Plass C; Weichenhan D; Hess J
    Epigenetics; 2016; 11(1):61-73. PubMed ID: 26786582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The DNA methylation landscape of
    Bockhorst C; Dietrich J; Vogt TJ; Stauber RH; Strieth S; Bootz F; Dietrich D; Vos L
    Epigenomics; 2021 Jan; 13(2):113-127. PubMed ID: 33351665
    [No Abstract]   [Full Text] [Related]  

  • 4. PITX2 and PANCR DNA methylation predicts overall survival in patients with head and neck squamous cell carcinoma.
    Sailer V; Holmes EE; Gevensleben H; Goltz D; Dröge F; de Vos L; Franzen A; Schröck F; Bootz F; Kristiansen G; Schröck A; Dietrich D
    Oncotarget; 2016 Nov; 7(46):75827-75838. PubMed ID: 27716615
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Sailer V; Holmes EE; Gevensleben H; Goltz D; Dröge F; Franzen A; Dietrich J; Kristiansen G; Bootz F; Schröck A; Dietrich D
    Clin Epigenetics; 2017; 9():12. PubMed ID: 28174607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-1 (PDCD1) promoter methylation in Merkel cell carcinoma: prognostic relevance and relationship with clinico-pathological parameters.
    Ricci C; Morandi L; Righi A; Gibertoni D; Maletta F; Ambrosi F; Agostinelli C; Uccella S; Asioli S; Sessa F; Pellilli M; Maragliano R; La Rosa S; Papotti MG; Asioli S
    Mod Pathol; 2019 Sep; 32(9):1359-1372. PubMed ID: 30976104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intragenic DNA methylation of PITX1 and the adjacent long non-coding RNA C5orf66-AS1 are prognostic biomarkers in patients with head and neck squamous cell carcinomas.
    Sailer V; Charpentier A; Dietrich J; Vogt TJ; Franzen A; Bootz F; Dietrich D; Schroeck A
    PLoS One; 2018; 13(2):e0192742. PubMed ID: 29425237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NDN and CD1A are novel prognostic methylation markers in patients with head and neck squamous carcinomas.
    Virani S; Bellile E; Bradford CR; Carey TE; Chepeha DB; Colacino JA; Helman JI; McHugh JB; Peterson LA; Sartor MA; Taylor JM; Walline HM; Wolf GT; Rozek LS
    BMC Cancer; 2015 Oct; 15():825. PubMed ID: 26518708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival.
    Dubot C; Bernard V; Sablin MP; Vacher S; Chemlali W; Schnitzler A; Pierron G; Ait Rais K; Bessoltane N; Jeannot E; Klijanienko J; Mariani O; Jouffroy T; Calugaru V; Hoffmann C; Lesnik M; Badois N; Berger F; Le Tourneau C; Kamal M; Bieche I
    Eur J Cancer; 2018 Mar; 91():47-55. PubMed ID: 29331751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Site-specific methylation patterns of the GAL and GALR1/2 genes in head and neck cancer: Potential utility as biomarkers for prognosis.
    Misawa K; Mochizuki D; Endo S; Mima M; Misawa Y; Imai A; Shinmura K; Kanazawa T; Carey TE; Mineta H
    Mol Carcinog; 2017 Mar; 56(3):1107-1116. PubMed ID: 27685843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of aberrant promoter hypermethylation of tumor-related genes in early-stage head and neck cancer.
    Misawa K; Mochizuki D; Imai A; Endo S; Mima M; Misawa Y; Kanazawa T; Carey TE; Mineta H
    Oncotarget; 2016 May; 7(18):26087-98. PubMed ID: 27027429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein expression and promoter methylation of the candidate biomarker TCF21 in head and neck squamous cell carcinoma.
    Weiss D; Stockmann C; Schrödter K; Rudack C
    Cell Oncol (Dordr); 2013 Jun; 36(3):213-24. PubMed ID: 23529585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MiR-21 as prognostic biomarker in head and neck squamous cell carcinoma patients undergoing an organ preservation protocol.
    Arantes LM; Laus AC; Melendez ME; de Carvalho AC; Sorroche BP; De Marchi PR; Evangelista AF; Scapulatempo-Neto C; de Souza Viana L; Carvalho AL
    Oncotarget; 2017 Feb; 8(6):9911-9921. PubMed ID: 28039483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aberrant methylation inactivates somatostatin and somatostatin receptor type 1 in head and neck squamous cell carcinoma.
    Misawa K; Misawa Y; Kondo H; Mochizuki D; Imai A; Fukushima H; Uehara T; Kanazawa T; Mineta H
    PLoS One; 2015; 10(3):e0118588. PubMed ID: 25734919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Association and Clinical Significance of CDKN2A Promoter Methylation in Head and Neck Squamous Cell Carcinoma: a Meta-Analysis.
    Zhou C; Shen Z; Ye D; Li Q; Deng H; Liu H; Li J
    Cell Physiol Biochem; 2018; 50(3):868-882. PubMed ID: 30355925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The neuropeptide genes
    Misawa K; Mima M; Imai A; Mochizuki D; Misawa Y; Endo S; Ishikawa R; Kanazawa T; Mineta H
    Clin Epigenetics; 2018; 10():52. PubMed ID: 29682090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating Cell-Free SEPT9 DNA Methylation in Blood Is a Biomarker for Minimal Residual Disease Detection in Head and Neck Squamous Cell Carcinoma Patients.
    Dietrich D; Weider S; de Vos L; Vogt TJ; Färber M; Zarbl R; Hunecke A; Glosch AK; Gabrielpillai J; Bootz F; Bauernfeind FG; Kramer FJ; Kristiansen G; Brossart P; Strieth S; Franzen A
    Clin Chem; 2023 Sep; 69(9):1050-1061. PubMed ID: 37477541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of promoter hypermethylation in salivary rinses as a biomarker for head and neck squamous cell carcinoma surveillance.
    Carvalho AL; Henrique R; Jeronimo C; Nayak CS; Reddy AN; Hoque MO; Chang S; Brait M; Jiang WW; Kim MM; Claybourne Q; Goldenberg D; Khan Z; Khan T; Westra WH; Sidransky D; Koch W; Califano JA
    Clin Cancer Res; 2011 Jul; 17(14):4782-9. PubMed ID: 21628494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of gene methylation in surgical margin imprints with locoregional recurrence in head and neck squamous cell carcinoma.
    Hayashi M; Wu G; Roh JL; Chang X; Li X; Ahn J; Goldsmith M; Khan Z; Bishop J; Zhang Z; Zhou XC; Richmon J; Agrawal N; Koch WM
    Cancer; 2015 Jun; 121(12):1957-65. PubMed ID: 25773145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibroblast growth factor (FGF), FGF receptor (FGFR), and cyclin D1 (CCND1) DNA methylation in head and neck squamous cell carcinomas is associated with transcriptional activity, gene amplification, human papillomavirus (HPV) status, and sensitivity to tyrosine kinase inhibitors.
    Bao Y; Gabrielpillai J; Dietrich J; Zarbl R; Strieth S; Schröck F; Dietrich D
    Clin Epigenetics; 2021 Dec; 13(1):228. PubMed ID: 34933671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.